HomeNovelAvalon GloboCare Announces Key U.S. Patent Issue for Several Novel QTY Coded Modified Cytokine and Chemokine Protein Receptor Molecules
Avalon GloboCare Announces Key U.S. Patent Issue for Several Novel QTY Coded Modified Cytokine and Chemokine Protein Receptor Molecules
January 17, 2023
Patent jointly filed with Massachusetts Institute of Technology (MIT)
FREEHOLD, NJ, January 17, 2023 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies, therapeutics and laboratory testing provider, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. No. 11,555,060 entitled “QTY Fc Fusion Water Soluble Receptor Proteins”. The issued claims relate to the material composition and methodology for multiple novel QTY-coded modified cytokine and chemokine protein receptor molecules. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).
The “QTY Code” is an innovative technology that can make it difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, greatly improving the solubility of designer peptides and proteins, thereby expanding the repertoire of selected therapeutic targets against cancer and other diseases.
“We are delighted to have obtained this key patent from the USPTO which broadens our intellectual property portfolio,” said David Jin, MD, Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We have jointly filed 16 patent applications, co-invented with key strategic partners, including a top 5 US university, a leading research and education center in Europe, as well as a leading multinational developer of cell therapies in the field of oncology and this issue further strengthens our position as a leader in immuno-oncology and cellular medicines.”
“The QTY code protein design platform, which was co-developed with Professor Shuguang Zhang’s lab at MIT, can transform water-insoluble proteins that normally reside within cell membranes – and which can be difficult to process within the laboratory – into water soluble proteins that can potentially be used in many clinical applications. The resulting soluble, antibody-like cytokine/chemokine receptors derived using the QTY protein design have many potential applications including mitigation of the COVID-19-associated “cytokine storm” and delivery of cellular immunotherapy, as well as l “expanding the range of therapeutic targets that CAR-T cell therapies can target,” concluded Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to the development and delivery of innovative and transformative cell therapies, precision diagnostics, and clinical laboratory services. Avalon also provides strategic consulting and outsourcing services to facilitate and enhance the growth and development of its clients, as well as competitiveness in the CellTech and Healthcare industry markets. Through its subsidiary structure with unique integration of industry verticals from innovative R&D to automated biomanufacturing and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), of exosomes (ACTEX™) and therapeutic regenerative immunotherapy. For more information about Avalon GloboCare, visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare developments, follow our twitter @avalongc_avco
Certain statements contained in this press release may constitute “forward-looking statements”. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statements that are not directly related to current or historical facts, including statements regarding potential transaction and financing and conditions for the closing and operation of Laboratory Services. Actual results may differ materially from those indicated by such forward-looking statements due to various important factors as disclosed in our filings with the Securities and Exchange Commission located on their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes and results may differ materially due to more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions and policy changes governmental and public. The forward-looking statements included in this press release represent the views of the Company as of the date of this press release, and those views could change. However, while the Company may choose to update these forward-looking statements in the future, the Company expressly disclaims any obligation to do so. These forward-looking statements should not be relied upon to represent the views of the Company as of any date subsequent to the date of the press release.